Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Migraine is a common neurological disorder causing moderate to severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. This research aims to evaluate the safety and effectiveness of ubrogepant, a medication approved for adults, in treating acute migraine attacks in children and adolescents aged 6 to 17 years. The study includes two groups a pharmacokinetic PK cohort for younger children and a main randomized study involving both children and adolescents. Participants aged 6 to 11 in the PK cohort will receive two different doses of ubrogepant to determine the appropriate dose for the main study. In the main study, after dose selection, children aged 6 to 11 and adolescents aged 12 to 17 will be randomly assigned to receive either a low dose, high dose of ubrogepant, or placebo, with a 1 in 3 chance of placebo assignment. For qualifying migraine attacks, participants will take oral tablets of the assigned study intervention and may take a second dose or rescue medication at least 2 hours later if the headache persists. Participants will attend regular visits at a hospital or clinic for up to 6 months. Researchers will monitor the effects of treatment through medical assessments, blood tests, side effect checks, and questionnaires. The main outcome measured is the percentage of participants who are free from pain 2 hours after the initial dose. Safety and tolerability will also be assessed throughout the study duration.